With this type of sales interest, Freedom Leaf is projecting revenue of $2,000,000 for the Hempology product line for 2018

LAS VEGAS, NV, Feb. 28, 2018 (GLOBE NEWSWIRE) — Freedom Leaf, Inc. (OTCQB:FRLF), a group of diversified, international, vertically-integrated Cannabis/Hemp business and media companies, today announced that it is developing multiple strategic partnerships through their wholly owned extraction division Leafceuticals Inc., and through their exclusively owned CBD product line Hempology.

Freedom Leaf has signed a National Distribution Agreement with Quality Products Distribution Inc., the distributor of the Accuvape vaporizer line. Hilary Dulany, CEO of Quality Products Distribution Inc., signed the agreement alongside Clifford Perry, CEO of Freedom Leaf, for distribution rights of the Hempology CBD line to their large network of retail stores across the country. With this type of sales interest, Freedom Leaf is projecting revenue of $2,000,000 for the Hempology product line for 2018.

Chris Thompson, Freedom Leaf’s Director of Digital Marketing, who helped close the Distribution Agreement, explained, “Signing a national distributor like Quality Products Distribution Inc. was one of our major goals with the Hempology line. Now that Hilary’s experienced sales team will be presenting our CBD products to dispensaries and retail stores, we expect a steady growth of wholesale orders in the coming weeks.”

In addition to the new Distribution Agreement, the Hempology CBD product line will also now be available in brick and mortar retail stores in over 10 states due to a large influx of wholesale orders from the recent Champs Trade Show and Tobacco Plus Expo in Las Vegas.

Freedom Leaf CEO and Co-Founder, Clifford Perry, stated, “We are creating a strong foundation for our international company through multiple positive relationships with key industry players. These strategic partnerships will continue to bring Freedom Leaf to the forefront of the emerging Cannabis/Hemp industry.”

Through the strategic partnership with manufacturer NutraFuels (OTCMKTS: NTFU), Freedom Leaf will be able to capitalize on the full retail value of the first industrial hemp CBD extraction by manufacturing the Hempology line with their own extracted CBD. This move will cut production costs of the Hempology CBD line and moves Freedom Leaf towards being a fully vertically-integrated company.

About Freedom Leaf®

Freedom Leaf, Inc., The Marijuana Legalization Company®, is a fully-reporting and audited, publicly-traded company trading under the symbol (OTCQB: FRLF), a group of diversified, international, vertically-integrated Cannabis/Hemp/CBD businesses and media companies

Freedom Leaf, Inc. is a leading, go-to resource in the cannabis, medical and recreational marijuana, CBD and industrial hemp industries. It is involved in mergers and acquisitions in these industries, including acceleration and spin offs of new companies involved in those industries.

Freedom Leaf Inc.‘s flagship publication is Freedom Leaf Magazine, The Good News in Marijuana Reform. The company produces a portfolio of news, print and digital multi-media verticals, websites, and web advertising, for the ever changing emerging cannabis, medical marijuana and industrial hemp industry. The Company also controls LaMarihuana.com, the world’s leading Spanish publication focused on these industries.

Statements in this press release that are not strictly historical are “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by phrases such as Freedom Leaf, Inc. or its management “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates” or other words or phrases of similar import. Similarly, statements herein that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Factors that could cause or contribute to differences include the uncertainty regarding viability and market acceptance of the Company’s products and services, changes in relationships with third parties, and other factors described in the Company’s most recent periodic filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K dated June 30, 2016 and quarterly reports on Form 10-Q.

Dr. Hongxiang Hui, MD, Ph.D has been appointed to the advisory board of NTFU and will serve as its Chief Medical Advisor. Dr. Hui is Director of American Realyoung Institute for Advanced Medicine, and a Principle Scientist at UCLA – he has been a member of the research faculty since 2002. Dr. Hui received his MD, and PhD degree in molecular biology from FMMU (The Fourth Military Medical University), PR. China. Prior to joining the UCLA faculty, he was a Post-doc at UCLA and UT Austin, and an associate professor at FMMU. Dr. Hui is an expert on metabolic diseases, biocenology and wellness. He is the author of over 150 scientific papers and dozens of patents on metabolic and biocenology studies. Dr. Hui is an associate editor of Pancreas and Frontier in Gastrointestinal Science, and serves as editor board on 8 international professional journals in nutrition and precision medicine. Dr.Hui is an active consultant for government and industry in medical and biotechnological areas. He is a member of Guangdong FDA advisory committee; the Chief Scientific Officer for a Hong Kong publicly listed company, the executive Chairman of scientific advisory board of The Pacific-Asia Precision Medicine Forum.

As chief medical advisor Dr. Hui will advise, license and co develop over the counter (OTC) nutraceutical products that will support various daily health and wellness uses starting with and focusing on diabetes and obesity. The company will utilize the doctor’s patented, researched driven, naturally derived wellness formulations and technologies and package them using NutraFuels unique metered dosing deliver systems.

NutraFuels Chief Executive Officer Edgar Ward states, “We are honored and pleased to be working with Dr. Hui; his credentials, experience, and successes are admirable and a perfect fit for our company. The applications and technologies Dr. Hui has to offer are research driven, clinically proven and cater to a number of health and wellness applications. We are grateful and excited to be a part of something we believe will help and support millions of people that are dealing with daily health and wellness issues.”

About NutraFuels, Inc.

NTFU was founded in 2010, to manufacture, distribute and market a line of oral spray nutritional dietary products to consumers, retailers and wholesale outlets. Oral spray delivery systems are recognized by many as an effective methodology for delivery of pharmaceutical and nutraceutical products. Oral spray delivery is recognized by consumers for its convenience, dosage precision and timely assimilation into the body. NTFU’s product line consists of vitamins and nutrients in an aqueous solution, orally delivered through a non-aerosol pump. NTFU’s products are sprayed into the mouth in the form of a fine mist entering the delicate tissue of the mouth. The nutrients are delivered into the bloodstream and assimilated throughout the body more quickly than traditional methods, avoiding the solubility and absorption problems common with most ingested vitamins and nutritional supplements in pill or capsule form. For more information please visit our corporate website. www.NutraFuels.com

Safe Harbor Statement

This press release contains forward-looking statements, particularly as related to, among other things, the business plans of NutraFuels, Inc statements relating to goals, plans and projections regarding the NutraFuels’ financial position and business strategy. The words or phrases “would be,” “will allow,” “intends to,” “may result,” “are expected to,” “will continue,” “anticipates,” “expects,” “estimate,” “project,” “indicate,” “could,” “potentially,” “should,” “believe,” “think”, “considers” or similar expressions are intended to identify “forward-looking statements.” These forward-looking statements fall within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 and are subject to the safe harbor created by these sections. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Such forward-looking statements are based on current expectations, involve known and unknown risks, a reliance on third parties for information, transactions or orders that may be cancelled, and other factors that may cause our actual results, performance or achievements, or developments in our industry, to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from anticipated results include risks and uncertainties related to the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic reports and on documents we file from time to time with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. NutraFuels cautions readers not to place undue reliance on such statements. NutraFuels does not undertake, and NutraFuels specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement. Actual results may differ materially from NutraFuels’ expectations and estimates.